JP2017042172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017042172A5 JP2017042172A5 JP2016230258A JP2016230258A JP2017042172A5 JP 2017042172 A5 JP2017042172 A5 JP 2017042172A5 JP 2016230258 A JP2016230258 A JP 2016230258A JP 2016230258 A JP2016230258 A JP 2016230258A JP 2017042172 A5 JP2017042172 A5 JP 2017042172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- composition according
- seq
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 230000001575 pathological effect Effects 0.000 claims 4
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000034799 Tauopathies Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000007659 motor function Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 241001260012 Bursa Species 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100031013 Transgelin Human genes 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 238000010382 chemical cross-linking Methods 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 208000004209 confusion Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 206010013395 disorientation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000006742 locomotor activity Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011824 transgenic rat model Methods 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536339P | 2011-09-19 | 2011-09-19 | |
| US61/536,339 | 2011-09-19 | ||
| US201261653115P | 2012-05-30 | 2012-05-30 | |
| US61/653,115 | 2012-05-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530333A Division JP6253583B2 (ja) | 2011-09-19 | 2012-09-14 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017033138A Division JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Division JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017042172A JP2017042172A (ja) | 2017-03-02 |
| JP2017042172A5 true JP2017042172A5 (OSRAM) | 2017-04-06 |
| JP6360869B2 JP6360869B2 (ja) | 2018-07-18 |
Family
ID=47216372
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530333A Active JP6253583B2 (ja) | 2011-09-19 | 2012-09-14 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2016230258A Active JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017033138A Active JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Active JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018132100A Active JP6637124B2 (ja) | 2011-09-19 | 2018-07-12 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2019228943A Active JP6950981B2 (ja) | 2011-09-19 | 2019-12-19 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2021150176A Active JP7182316B2 (ja) | 2011-09-19 | 2021-09-15 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530333A Active JP6253583B2 (ja) | 2011-09-19 | 2012-09-14 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017033138A Active JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Active JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018132100A Active JP6637124B2 (ja) | 2011-09-19 | 2018-07-12 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2019228943A Active JP6950981B2 (ja) | 2011-09-19 | 2019-12-19 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2021150176A Active JP7182316B2 (ja) | 2011-09-19 | 2021-09-15 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9518101B2 (OSRAM) |
| EP (2) | EP3275461A1 (OSRAM) |
| JP (7) | JP6253583B2 (OSRAM) |
| KR (3) | KR102130439B1 (OSRAM) |
| CN (3) | CN104185640B (OSRAM) |
| AU (3) | AU2012311234B2 (OSRAM) |
| BR (1) | BR112014006376B1 (OSRAM) |
| CA (1) | CA2848346A1 (OSRAM) |
| CL (3) | CL2014000679A1 (OSRAM) |
| CY (1) | CY1119792T1 (OSRAM) |
| DK (1) | DK2758433T3 (OSRAM) |
| ES (1) | ES2656442T3 (OSRAM) |
| HR (1) | HRP20180083T8 (OSRAM) |
| HU (1) | HUE036177T2 (OSRAM) |
| IL (4) | IL231201B (OSRAM) |
| LT (1) | LT2758433T (OSRAM) |
| ME (1) | ME03008B (OSRAM) |
| MX (2) | MX347505B (OSRAM) |
| MY (1) | MY183989A (OSRAM) |
| PL (1) | PL2758433T3 (OSRAM) |
| PT (1) | PT2758433T (OSRAM) |
| RS (1) | RS56852B1 (OSRAM) |
| RU (2) | RU2645259C2 (OSRAM) |
| SG (4) | SG10201912964PA (OSRAM) |
| SI (1) | SI2758433T1 (OSRAM) |
| SM (1) | SMT201800109T1 (OSRAM) |
| TR (1) | TR201800669T4 (OSRAM) |
| UA (2) | UA115657C2 (OSRAM) |
| WO (1) | WO2013041962A1 (OSRAM) |
| ZA (1) | ZA201401333B (OSRAM) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703137B2 (en) * | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| UA115657C2 (uk) * | 2011-09-19 | 2017-12-11 | Аксон Ньюросайєнс Сє | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла |
| MX359555B (es) | 2012-07-03 | 2018-10-02 | Univ Washington | Anticuerpos para tau. |
| JP6290212B2 (ja) | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| EP3689904A1 (en) | 2013-03-13 | 2020-08-05 | Prothena Biosciences Limited | Tau immunotherapy |
| CN105899230B (zh) * | 2013-11-27 | 2020-06-09 | 伊皮埃里安股份有限公司 | 治疗tau病变的方法 |
| WO2015098963A1 (ja) * | 2013-12-26 | 2015-07-02 | 東亞合成株式会社 | カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド |
| US10400018B2 (en) | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| SG11201610446XA (en) * | 2014-06-26 | 2017-01-27 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| JP6679582B2 (ja) | 2014-09-30 | 2020-04-15 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | タウの動態測定 |
| CN112410339A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| RS61431B1 (sr) | 2014-11-19 | 2021-03-31 | Axon Neuroscience Se | Humanizovana antitela na tau u alchajmerovoj bolesti |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP4465050A3 (en) | 2015-06-05 | 2025-06-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EA036821B1 (ru) | 2015-07-06 | 2020-12-23 | Юсб Биофарма Срл | Тау-связывающие антитела |
| MX2017015817A (es) | 2015-07-06 | 2018-04-10 | Ucb Biopharma Sprl | Anticuerpos de union a tau. |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| GB201518675D0 (en) * | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP7481726B2 (ja) * | 2016-05-02 | 2024-05-13 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| KR102750101B1 (ko) * | 2016-05-02 | 2025-01-03 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| CA3252099A1 (en) | 2016-05-18 | 2025-06-05 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| KR101997319B1 (ko) | 2016-06-21 | 2019-07-08 | 전남대학교산학협력단 | 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용 |
| CN109562167A (zh) | 2016-08-09 | 2019-04-02 | 伊莱利利公司 | 联合治疗 |
| FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| EP3551220B1 (en) | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| CN110248959B (zh) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2018117647A1 (ko) | 2016-12-21 | 2018-06-28 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| WO2018178077A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| US20210147481A1 (en) * | 2017-04-21 | 2021-05-20 | Ohio University | Peptide-based inhibitors of mark family proteins |
| PE20200695A1 (es) | 2017-05-02 | 2020-06-16 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| JP7029718B2 (ja) * | 2017-07-31 | 2022-03-04 | 国立研究開発法人量子科学技術研究開発機構 | リン酸化タウタンパク質の測定方法 |
| US11791016B2 (en) | 2017-10-02 | 2023-10-17 | Neumora Therapeutics, Inc. | Methods and systems for computer-generated predictive application of neuroimaging and gene expression mapping data |
| US10829547B2 (en) | 2017-10-16 | 2020-11-10 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| AR113792A1 (es) * | 2017-10-25 | 2020-06-10 | Janssen Pharmaceuticals Inc | Composiciones de péptidos tau fosforilados y sus usos |
| CN119409835A (zh) * | 2017-10-27 | 2025-02-11 | 联脑科学公司 | Tau肽免疫原构建体 |
| WO2019120527A1 (en) * | 2017-12-20 | 2019-06-27 | Michael Heneka | Novel means and methods for treating neurodegenerative diseases |
| CN111918875A (zh) | 2018-03-11 | 2020-11-10 | 库罗什·沙帕桑 | 构象-特异性的抗神经毒性tau蛋白的抗体 |
| WO2019186276A2 (en) | 2018-03-28 | 2019-10-03 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
| RU2679080C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| RU2679059C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| KR102787585B1 (ko) * | 2018-05-03 | 2025-03-27 | 워싱턴 유니버시티 | 부위-특이적 타우 인산화에 기반한 진단 및 치료 방법 |
| US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
| PE20210346A1 (es) | 2018-07-03 | 2021-02-25 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau |
| CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| US20220273779A1 (en) * | 2018-11-19 | 2022-09-01 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
| WO2020120644A1 (en) * | 2018-12-13 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| CN113597431B (zh) * | 2019-02-08 | 2025-02-21 | 普罗塞纳生物科学有限公司 | 识别Tau的抗体 |
| BR112021014794A2 (pt) | 2019-02-08 | 2021-10-05 | Ac Immune S.A. | Método de administração segura de vacina de peptídeo de tau fosforilada |
| PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| WO2020193520A1 (en) * | 2019-03-25 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
| EP3965817A4 (en) * | 2019-04-24 | 2023-11-22 | Janssen Pharmaceuticals, Inc. | HETEROLOGICAL ADMINISTRATION OF TAU VACCINES |
| BR112021021062A2 (pt) * | 2019-05-31 | 2021-12-14 | Lilly Co Eli | Compostos e métodos que alvejam tau humano |
| GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| TWI832183B (zh) * | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
| JP7780200B2 (ja) * | 2019-08-13 | 2025-12-04 | ワシントン・ユニバーシティ | Ｍｔｂｒタウアイソフォームを検出する方法およびその使用 |
| CN114531877B (zh) * | 2019-08-15 | 2024-11-15 | 学校法人东京医科大学 | 不受clsp阻碍物质影响的clsp衍生物和clsp活性的增强/保护剂 |
| WO2021048619A2 (en) | 2019-09-09 | 2021-03-18 | Axon Neuroscience Se | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| JP7668027B2 (ja) | 2019-09-10 | 2025-04-24 | ワシントン・ユニバーシティ | 部位特異的タウリン酸化をベースとする診断および処置のための血液ベースアッセイ |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| IL270800A (en) * | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
| CN110841059A (zh) * | 2019-12-03 | 2020-02-28 | 南通大学 | 老年性痴呆小鼠模型的制备方法 |
| MX2022009607A (es) * | 2020-02-05 | 2022-09-02 | Sumitomo Pharma Co Ltd | Agente de determinacion y metodo de determinacion de taupatia y enfermedades relacionadas con la demencia. |
| JP2023526500A (ja) * | 2020-05-19 | 2023-06-21 | オター プロシーナ リミテッド | アルツハイマー病の処置のためのマルチエピトープワクチン |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| IL300347A (en) * | 2020-08-07 | 2023-04-01 | Othair Prothena Ltd | Multi-shot vaccine for the treatment of Alzheimer's disease |
| KR20230080398A (ko) * | 2020-08-07 | 2023-06-07 | 프로테나 바이오사이언시즈 리미티드 | 알츠하이머 질환 치료용 tau 백신 |
| WO2022115705A2 (en) | 2020-11-30 | 2022-06-02 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| IL303737A (en) * | 2020-12-18 | 2023-08-01 | Sangamo Therapeutics Inc | Improved pharmaceutical compositions containing adeno-associated viral vector |
| AU2022219986A1 (en) * | 2021-02-14 | 2023-08-31 | Prothena Biosciences Limited | Methods of using antibodies recognizing tau |
| BR112023014151A2 (pt) * | 2021-02-19 | 2023-10-10 | Eisai R&D Man Co Ltd | Anticorpo tau anti-pt217 |
| US12144815B2 (en) | 2021-02-23 | 2024-11-19 | Hoth Therapeutics, Inc. | Use of aprepitant for treating Alzheimer's disease |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| CN113430230A (zh) * | 2021-06-24 | 2021-09-24 | 南通大学 | tau截断体蛋白在诱导tau病理聚集中的应用 |
| US20250035633A1 (en) * | 2021-10-08 | 2025-01-30 | Arbele Limited | Compositions and methods for detecting cadherin-17 protein |
| CN113861441A (zh) * | 2021-10-28 | 2021-12-31 | 南开大学 | 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN116554342A (zh) * | 2022-01-29 | 2023-08-08 | 元本(珠海横琴)生物科技有限公司 | 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株 |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025019332A1 (en) * | 2023-07-14 | 2025-01-23 | Alzpath, Inc. | Methods for remote blood collection, extraction and analysis of neuro biomarkers |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
| CN117624354B (zh) * | 2023-11-30 | 2024-07-12 | 无锡傲锐东源生物科技有限公司 | 一种抗人乙酰化tau281兔单克隆抗体及其应用 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| CA2067194C (en) | 1989-10-05 | 2003-03-18 | Glenn Kawasaki | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| ATE386115T1 (de) * | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| CA2169635C (en) | 1993-08-26 | 2002-11-12 | Dennis A. Carson | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| DE69535901D1 (de) * | 1994-10-28 | 2009-01-29 | Max Planck Gesellschaft | Proteinkinase npk-110 |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5643207A (en) | 1995-04-28 | 1997-07-01 | Medtronic, Inc. | Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| CA2234685A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| US5820589A (en) | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US6198966B1 (en) | 1999-02-26 | 2001-03-06 | Medtronic, Inc. | Recirculating implantable drug delivery system |
| JP3383618B2 (ja) | 1999-08-18 | 2003-03-04 | 松下電器産業株式会社 | 移動体通信端末装置及び受信強度検出方法 |
| ATE326700T1 (de) * | 1999-09-09 | 2006-06-15 | Max Planck Gesellschaft | SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß |
| WO2001018544A1 (en) * | 1999-09-09 | 2001-03-15 | Mcgill University | Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases |
| US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| DE50111493D1 (de) | 2001-09-03 | 2007-01-04 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Antigen-Mimotope und Vakzine gegen Krebserkrankungen |
| TWI226905B (en) | 2001-10-19 | 2005-01-21 | Bioware Technology Co Ltd | Low pressure-accelerated particle gene gun |
| DE60320258T2 (de) * | 2002-07-12 | 2009-06-25 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Transgenes tier welches das trunkierte alzheimer tau protein exprimiert |
| AU2003250102B2 (en) * | 2002-07-24 | 2009-09-17 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| US7521230B2 (en) * | 2002-10-16 | 2009-04-21 | Board Of Regents Of The University Of Nebraska | Nucleic acid encoding a Brain Derived Tau Kinase polypeptide and methods of use thereof |
| EP1516930A1 (en) | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
| CN1867584A (zh) | 2003-10-08 | 2006-11-22 | E生物科学公司 | 天然免疫球蛋白结合试剂及其制造和使用方法 |
| CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8377875B2 (en) | 2007-01-11 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Therapeutics based on tau/microtubule dynamics |
| EP2149584B1 (en) * | 2007-04-20 | 2017-12-13 | The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
| EP2171089B1 (en) | 2007-06-25 | 2014-01-22 | Universität Duisburg-Essen | Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS |
| AU2010286501B2 (en) * | 2009-08-28 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Antibodies that bind Tau oligomers |
| WO2011053565A2 (en) * | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| KR20120101053A (ko) * | 2009-11-06 | 2012-09-12 | 더 제이. 데이비드 글래드스톤 인스티튜트 | 타우 레벨을 조절하기 위한 방법 및 조성물 |
| DK2501716T3 (en) * | 2009-11-19 | 2015-04-07 | Solis Biodyne Oü | Formations to increase polypeptidstabilitet and activity and related practices |
| CL2010000019A1 (es) * | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
| UA115657C2 (uk) * | 2011-09-19 | 2017-12-11 | Аксон Ньюросайєнс Сє | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2012
- 2012-09-14 UA UAA201404170A patent/UA115657C2/uk unknown
- 2012-09-14 LT LTEP12788639.8T patent/LT2758433T/lt unknown
- 2012-09-14 MX MX2014003357A patent/MX347505B/es active IP Right Grant
- 2012-09-14 CN CN201280056856.XA patent/CN104185640B/zh active Active
- 2012-09-14 MX MX2017005573A patent/MX391157B/es unknown
- 2012-09-14 DK DK12788639.8T patent/DK2758433T3/en active
- 2012-09-14 MY MYPI2014000803A patent/MY183989A/en unknown
- 2012-09-14 RU RU2014115481A patent/RU2645259C2/ru active
- 2012-09-14 RS RS20180054A patent/RS56852B1/sr unknown
- 2012-09-14 SG SG10201912964PA patent/SG10201912964PA/en unknown
- 2012-09-14 KR KR1020147010525A patent/KR102130439B1/ko active Active
- 2012-09-14 KR KR1020207018712A patent/KR102285743B1/ko active Active
- 2012-09-14 SI SI201231187T patent/SI2758433T1/en unknown
- 2012-09-14 SG SG11201400125RA patent/SG11201400125RA/en unknown
- 2012-09-14 BR BR112014006376-1A patent/BR112014006376B1/pt active IP Right Grant
- 2012-09-14 PL PL12788639T patent/PL2758433T3/pl unknown
- 2012-09-14 AU AU2012311234A patent/AU2012311234B2/en active Active
- 2012-09-14 SG SG10201912955PA patent/SG10201912955PA/en unknown
- 2012-09-14 EP EP17190247.1A patent/EP3275461A1/en active Pending
- 2012-09-14 SG SG10201703771WA patent/SG10201703771WA/en unknown
- 2012-09-14 KR KR1020217024024A patent/KR20210099167A/ko not_active Ceased
- 2012-09-14 CN CN201810662577.7A patent/CN109265543B/zh active Active
- 2012-09-14 WO PCT/IB2012/002246 patent/WO2013041962A1/en not_active Ceased
- 2012-09-14 US US14/345,561 patent/US9518101B2/en active Active
- 2012-09-14 HR HRP20180083TT patent/HRP20180083T8/hr unknown
- 2012-09-14 SM SM20180109T patent/SMT201800109T1/it unknown
- 2012-09-14 UA UAA201706478A patent/UA123390C2/uk unknown
- 2012-09-14 CA CA2848346A patent/CA2848346A1/en not_active Abandoned
- 2012-09-14 TR TR2018/00669T patent/TR201800669T4/tr unknown
- 2012-09-14 EP EP12788639.8A patent/EP2758433B1/en active Active
- 2012-09-14 RU RU2018102103A patent/RU2018102103A/ru unknown
- 2012-09-14 CN CN202210373330.XA patent/CN115417916A/zh active Pending
- 2012-09-14 ME MEP-2018-18A patent/ME03008B/me unknown
- 2012-09-14 JP JP2014530333A patent/JP6253583B2/ja active Active
- 2012-09-14 PT PT127886398T patent/PT2758433T/pt unknown
- 2012-09-14 HU HUE12788639A patent/HUE036177T2/hu unknown
- 2012-09-14 ES ES12788639.8T patent/ES2656442T3/es active Active
-
2014
- 2014-02-21 ZA ZA2014/01333A patent/ZA201401333B/en unknown
- 2014-02-27 IL IL231201A patent/IL231201B/en active IP Right Grant
- 2014-03-19 CL CL2014000679A patent/CL2014000679A1/es unknown
-
2015
- 2015-05-14 CL CL2015001314A patent/CL2015001314A1/es unknown
-
2016
- 2016-01-27 CL CL2016000215A patent/CL2016000215A1/es unknown
- 2016-11-03 US US15/342,629 patent/US9828421B2/en active Active
- 2016-11-28 JP JP2016230258A patent/JP6360869B2/ja active Active
-
2017
- 2017-02-24 JP JP2017033138A patent/JP6286590B2/ja active Active
- 2017-05-19 US US15/599,685 patent/US9845352B2/en active Active
- 2017-11-02 US US15/801,341 patent/US11098106B2/en active Active
- 2017-12-07 AU AU2017272259A patent/AU2017272259B2/en active Active
-
2018
- 2018-01-17 CY CY20181100058T patent/CY1119792T1/el unknown
- 2018-03-27 JP JP2018059946A patent/JP6499345B2/ja active Active
- 2018-06-03 IL IL259775A patent/IL259775B/en active IP Right Grant
- 2018-07-12 JP JP2018132100A patent/JP6637124B2/ja active Active
-
2019
- 2019-12-19 JP JP2019228943A patent/JP6950981B2/ja active Active
-
2020
- 2020-01-29 AU AU2020200624A patent/AU2020200624B2/en active Active
- 2020-05-04 IL IL274440A patent/IL274440B/en unknown
-
2021
- 2021-07-27 US US17/443,779 patent/US12404322B2/en active Active
- 2021-09-15 JP JP2021150176A patent/JP7182316B2/ja active Active
- 2021-11-02 IL IL287794A patent/IL287794A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017042172A5 (OSRAM) | ||
| RU2018102103A (ru) | Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера | |
| US11312763B2 (en) | Anti-N3pGlu amyloid beta peptide antibodies and uses thereof | |
| JP6424210B2 (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| JP2019511222A5 (OSRAM) | ||
| JP2014530597A5 (OSRAM) | ||
| JP2016528247A5 (OSRAM) | ||
| Panza et al. | Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab | |
| CA2729414A1 (en) | Vaccine against amyloid folding intermediate | |
| JP2018530574A5 (OSRAM) | ||
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| JP5474807B2 (ja) | 改変アミロイドβペプチド | |
| JP6949012B2 (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| JP2014534956A5 (OSRAM) | ||
| JP2018529661A5 (OSRAM) | ||
| CN106163540A (zh) | 用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合 | |
| EP4107166A1 (en) | Heteroaryl compounds for treatment of complement factor d mediated disorders | |
| TW202233666A (zh) | 減少人類對象中之ｔａｕ的方法 | |
| TW202523689A (zh) | 治療脊髓損傷及疼痛之方法 | |
| JP2017202977A (ja) | アミロイドβ蛋白質オリゴマー用モノクローナル抗体及びその利用 | |
| EP4619103A1 (en) | Anti-n3pglu amyloid beta antibodies, doses, and uses thereof | |
| Rasool et al. | Amyloid β Immunotherapy | |
| HK40000304A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| HK40000304B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| NZ748496B2 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |